Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2618936
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: After 8 cycles of mFOLFOX 6 plus bevacizumab, patients receive UFT/LV with bevacizumab (until 5 cycles are completed or disease progression). And then, patients receive modified FOLFOX6 plus bevacizumab until disease progression.
Patients receive mFOLFOX6 plus bevacizumab until disease progression.
Primary outcome(s): disease control survival
Study Design: Parallel Randomized
创建时间：
2008-07-15
